Ronald A Ahrens Net Worth

The estimated Net Worth of Ronald A Ahrens is at least $422 Tysiąc dollars as of 9 May 2014. Ronald Ahrens owns over 6,000 units of HeartBeam Inc stock worth over $422,165 and over the last 11 years Ronald sold BEAT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ronald Ahrens BEAT stock SEC Form 4 insiders trading

Ronald has made over 2 trades of the HeartBeam Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Ronald bought 6,000 units of BEAT stock worth $44,220 on 9 May 2014.

The largest trade Ronald's ever made was buying 6,000 units of HeartBeam Inc stock on 9 May 2014 worth over $44,220. On average, Ronald trades about 2,750 units every 44 days since 2013. As of 9 May 2014 Ronald still owns at least 187,629 units of HeartBeam Inc stock.

You can see the complete history of Ronald Ahrens stock trades at the bottom of the page.

What's Ronald Ahrens's mailing address?

Ronald's mailing address filed with the SEC is 227 Washington St, Conshohocken, PA 19428, USA.

Insiders trading at HeartBeam Inc

Over the last 11 years, insiders at HeartBeam Inc have traded over $23,124,978 worth of HeartBeam Inc stock and bought 31,500 units worth $221,145 . The most active insiders traders include Joseph H Capper, Heather C Getz oraz Willem Elfrink. On average, HeartBeam Inc executives and independent directors trade stock every 32 days with the average trade being worth of $55,046. The most recent stock trade was executed by Urioste George De on 6 September 2024, trading 1,674 units of BEAT stock currently worth $3,917.

What does HeartBeam Inc do?

heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.

Complete history of Ronald Ahrens stock trades at HeartBeam Inc

HeartBeam Inc executives and stock owners

HeartBeam Inc executives and other stock owners filed with the SEC include:

• Joseph Capper,
  President, Chief Executive Officer, Director
• Heather Getz,
  Chief Financial Officer, Executive Vice President, Chief Administrative Officer
• Fred Broadway,
  President, BioTel Heart
• Daniel Wisniewski,
  Senior Vice President - Technical Operations
• Kirk Gorman,
  Independent Chairman of the Board
• Rebecca Rimel,
  Independent Director
• Anthony Conti,
  Independent Director
• Joseph Frick,
  Independent Director
• Stephan Rietiker,
  Director
• Robert Rubin,
  Independent Director
• Colin Hill,
  Independent Director
• Tiffany Olson,
  Independent Director
• Laura Dietch,
  Independent Director
• Dr. Branislav Vajdic Ph.D.,
  Founder, CEO & Director
• Richard D. Brounstein,
  Chief Financial Officer
• Manish Wadhwa,
  Chief Medical Officer
• Andrei Stoica,
  Chief Technology Officer
• Dr. Peter J. Fitzgerald FACC, M.D., Ph.D.,
  Chief Medical Officer
• Ken Persen,
  Chief Technology Officer
• Dr. Jon Hunt Ph.D.,
  Exec. VP & Chief Bus. Officer
• Alexei Shvilkin M.D.,
  Chief Medical Officer
• Dr. Dorin Panescu Ph.D.,
  Chief Technical Officer
• Alan Baumel,
  Chief Operating Officer
• Richard M. Ferrari,
  Exec. Chairman
• George Hrenko,
  Senior Vice President
• Stephen Rietiker,
  Director
• Michael Geldart,
  Senior Vice President
• Ronald A Ahrens,
  Director
• Eric N Prystowsky,
  Director
• Peter Ferola,
  SVP & General Counsel
• Kenneth Warwick Iii Nelson,
  Director
• Mark E Strome,
  10% owner
• Michael R Jaff,
  Director
• Willem Elfrink,
  Director
• Marga Ortigas Wedekind,
  Director
• Urioste George De,
  Director
• Richard Ferrari,
  Director
• Jon Patrick Hunt,
  Chief Business Officer
• Richard Brounstein,
  Chief Financial Officer
• Alan Baumel,
  Chief Operating Officer
• Kenneth Harry Persen,
  Chief Technology Officer
• Robert Paul Eno,
  President
• Branislav Vajdic,
  CHIEF EXECUTIVE OFFICER